Related Experiment Video

Updated: Mar 23, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

626

Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival

    Prescrire International
    |April 5, 2016
    PubMed

    Insights

    This study found that while radiological progression was delayed by 5 months, the trial design limited survival analysis. Researchers observed numerous adverse effects, some serious.

    Area of Science:

    • Oncology
    • Radiology
    • Clinical Trials

    Background:

    • Assessing the efficacy and safety of novel treatments in oncology is crucial.
    • Understanding treatment impact on radiological progression and survival is a key research area.

    Purpose of the Study:

    • To evaluate the effect of a treatment on radiological progression and survival.
    • To identify and document adverse events associated with the treatment.

    Main Methods:

    • A clinical trial was conducted to assess treatment outcomes.
    • Radiological progression and survival were monitored as endpoints.
    • Adverse events were systematically recorded.

    Main Results:

    • Radiological progression was delayed by an average of 5 months.
    • The trial design precluded a reliable analysis of survival data.
    • Numerous adverse effects were reported, with some being serious in nature.

    Conclusions:

    • The treatment demonstrated a delay in radiological progression.
    • Limitations in trial design impact the interpretation of survival data.
    • The occurrence of significant adverse events warrants careful consideration.

    More Related Videos

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    2.4K
    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

    An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

    Published on: September 12, 2019

    9.7K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    65
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.3K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K